|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27.02.26 - 13:03
|
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting (Business Wire)
|
|
|
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses from the Phase 3 OASIS-HAE and OASISplus studies. Results will be presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA.
“These data add to a growing body of evidence outlining the clinical value of DAWNZERA for people living with HAE, highlighting its potential to deliver meaningful improvement in HAE attack rate and quality of life, including for those switching from another long-term prophylactic therapy,” said Kenneth Newman, M.D., senior vice president, clinical development, Ionis. “We know that patients continue to seek out a treatment that meaningfully reduces attack frequency and severity while also addressing the administration and lifestyle burden of long-term therapy. The breadth of dat...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.02.26 - 13:06
|
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs (Business Wire)
|
|
|
- TRYNGOLZA® generated $108 million in net product sales in 2025, the first year of launch –
- Olezarsen sHTG launch preparations on track, sNDA submitted -
- Exceeded 2025 financial guidance, 2026 guidance reflects commitment to independently deliver a steady cadence of innovative medicines to patients -CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the fourth quarter and year ended December 31, 2025.
"2025 was a defining year for Ionis, marked by the successful execution of our first two independent launches and multiple positive data readouts across our pipeline, positioning Ionis for continued success in 2026,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “This year, we are poised for two additional independent launches of groundbreaking therapies — olezarsen for severe hypertriglyceridemia, our first launch in a broad patient population, and zilganersen for A...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
